← Back to Search

Neoantigen Peptide Vaccine for Pancreatic Cancer

Phase 1

Waitlist Available

Led By William E Gillanders, M.D.

Research Sponsored by Washington University School of Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through 30 days following completion of treatment (median follow-up of 107 days, full range of 88-157 days)

Awards & highlights

Study Summary

This trial is testing a cancer vaccine made from a patient's own tumor in order to see if it is safe and if it can create an immune response against the cancer.

Eligible Conditions

Pancreatic Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through 30 days following completion of treatment (median follow-up of 107 days, full range of 88-157 days)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through 30 days following completion of treatment (median follow-up of 107 days, full range of 88-157 days)

This trial's timeline: 3 weeks for screening, Varies for treatment, and through 30 days following completion of treatment (median follow-up of 107 days, full range of 88-157 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Safety of Neoantigen Peptide Vaccine as Measured by the Number of Serious Adverse Events

Secondary outcome measures

Immunogenicity of the Neoantigen Peptide Vaccine as Measured by ELISPOT Analysis

Immunogenicity of the Neoantigen Peptide Vaccine as Measured by Multiparametric Flow Cytometry

Trial Design

1Treatment groups

Experimental Treatment

Group I: Neoantigen Peptide VaccineExperimental Treatment3 Interventions

The schedule for vaccination will be Days 1, 4, 8, 15, and 22 (delays of up to 96 hours are allowed for each dose based on the adverse events experienced). Additional vaccinations will be given on Days 50 and 78 (+/- 2 weeks). The first vaccine dose may be administered following confirmation of disease-free status and within 90 days following date of repeat imaging. All study injections will be given subcutaneously and co-administered with poly-ICLC by a trained healthcare provider.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Poly ICLC

2014

Completed Phase 2

~270

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor

1,937 Previous Clinical Trials

2,297,860 Total Patients Enrolled

National Institutes of Health (NIH)NIH

2,705 Previous Clinical Trials

7,507,366 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,675 Previous Clinical Trials

40,926,965 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new study participants being recruited at this moment?

"According to clinicaltrials.gov, this trial is no longer enrolling patients as it was initially posted on February 13th 2020 and last modified on August 11th 2022. However, 698 other trials are actively looking for participants at the present moment."

Answered by AI

Has the Neoantigen Peptide Vaccine gained regulatory acceptance yet?

"Our in-house rating system at Power gave Neoantigen Peptide Vaccine a score of 1, as this is an early Phase 1 trial with limited safety and efficacy data."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

2020. "Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03956056.